(CercleFinance.com) – Equasens gains nearly 3% in Paris, while Stifel confirmed this morning its ‘hold’ rating on Equasens shares, with an unchanged price target of 66 euros.
The analyst reports that Equasens has confirmed the long-awaited acquisition of AD Apotheken Datenverarbeitung GmbH & Co. KG (ADV), a German company publishing pharmacy software which achieves a turnover estimated at around 5 ME.
Stifel believes that this target is small (2% market share) but very important from a strategic point of view. ‘The company aims to reach the top 3 within five years, which would require reaching >20% market share, a very unlikely objective in our eyes’, nevertheless adds the analysis office
Stifel recalls that Equasens has wanted to enter the pharmaceutical software market for years but that this acquisition will require more investment to grow, potentially putting the operating margin under pressure.